FibroGen (FGEN) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
FibroGen Reports Financial Results for the First Quarter of 2016
May 9, 2016 4:02 PM EDTContinued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data
Webcast Conference Call Scheduled for 4:30pm EST Today
SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) (FibroGen), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2016.
We are pleased with the progress of our major development programs across the board, said Thomas B. Neff, chief executive officer of FibroGen. FibroGen and our collaboration partners continue to advance the roxadustat global Phase 3 program in... More
